Skip to main content
. 2018 Jul 26;10(6):913–921. doi: 10.1080/19420862.2018.1474996

Figure 6.

Figure 6.

Importance of FcγRIII for IFN-γ release in response to IgG1 antibodies with CRS-inducing potential. (A-C) IFN-γ release was assessed using human whole blood stimulated for 24 h with (A) anti-CD52, either full-length IgG1 or F(ab’)2, (B) mAb1 with either an IgG1 or an IgG1 effector-null backbone (C) mAb2 with either an IgG1 or an IgG4 backbone. Bar graph represent the mean ± SEM fold-change in cytokine levels normalized to the untreated samples. (D,E) IFN-γ release was assessed using human whole blood pre-incubated with blocking anti-FcγR F(ab’)2 (FcγRI, FcγRII, or FcγRIII) and then stimulated for 24 h with (D) anti-CD52 or without anti-CD52 (E). P-values generated by one-way ANOVA followed by paired T-test of concentrations of blocked versus control samples (*p < 0.05, **p < 0.01, ***p < 0.001). Bars are represented as mean ± SEM. Donor responses shown are (A) n = 4, (B-D) n = 6. One representative experiment out of 2–3 experiments is shown.